A Phase 2 interventional study of Pneumococcal Conjugate Vaccine formulation 1 and Pneumococcal Conjugate Vaccine formulation 2 in Pneumococcal Immunisation, Diphtheria Immunisation and Tetanus Immunisation, sponsored by Sanofi Pasteur, a Sanofi Company. Completed at 57 sites in 4 countries. Open to participants aged 42 Days to 15 Months, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-08.
Sponsored by Sanofi Pasteur, a Sanofi Company (part of Sanofi) · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies testing Chickenpox Vaccine in Chickenpox — 5 open to participants now, 7 under way, 4 of them phase 3. Chickenpox Vaccine · Chickenpox.
Among the 36 studies testing Chickenpox Vaccine in Chickenpox, this one is the 9th largest by enrollment, is the only one that started in 2020, is one of 2 in phase 2, and was the 25th registered.
180 studies on the registry are indexed under Chickenpox; 28 are open to participants now.
Browse Chickenpox studies →5 of the 36 studies testing Chickenpox Vaccine in Chickenpox are open now, in 7 countries. Recruiting first, the newest first:
SK Bioscience Co., Ltd. · Sites in Honduras, Philippines, Korea, Republic of and 1 more country
Ages 12 mo–12 yrs · Healthy volunteers
University Hospital, Geneva · Sites in Switzerland
Ages up to 18
Sinovac (Dalian) Vaccine Technology Co., Ltd. · Sites in China
Ages 8–16 · Healthy volunteers
Sinovac (Dalian) Vaccine Technology Co., Ltd. · Sites in China
Ages 1–17 · Healthy volunteers
Sinovac (Dalian) Vaccine Technology Co., Ltd. · Sites in Vietnam
Ages 1–12 · Healthy volunteers
By country, each count listing its studies:
Chickenpox Vaccine: first FDA approval 1995 (Varivax). What it is approved for, and how studies give it, is on its page →
Of the 16 Chickenpox studies recruiting now, 3 (19%) set no upper age limit and 13 (81%) stop at 75 or younger; 12 take children under 18; 13 take healthy volunteers.
This study: 42 Days to 15 Months · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 6 · Phase 3 14 · Phase 4 14
First in 1998; this study’s year is marked. 1 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 852 is above the median of 475 across 149 interventional studies indexed under Chickenpox.
Median enrollment 404 across the 36 interventional studies. Of the 20 that completed or were terminated, 5 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 36 have an industry lead sponsor. The 10 most frequent:
This study is registered under Sanofi Pasteur, a Sanofi Company, one of the names counted as Sanofi. Under that name alone:
Sanofi Pasteur, a Sanofi Company is the lead sponsor of 374 studies on the registry; 4 are open to participants now.
Of its 94 completed or terminated interventional studies of FDA-regulated products, 73 (78%) have results posted.
Sanofi has 6 studies filed under Chickenpox — fewer than ten, so there is no comparison to draw.
1 of the studies testing Chickenpox Vaccine in Chickenpox that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07415252Phase 3SK Bioscience Co., Ltd.SkyVaricella® (NBP608) Vaccine With Lower Potencies in Healthy Children Aged 12 Months to 12 Years | 2027-02-13 |
Add it to your calendar (.ics) → With an account.
Among the 36 studies testing Chickenpox Vaccine in Chickenpox, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Primary objectives:
Secondary objectives:
For toddlers, the duration of each participant's participation in the study will be approximately 6 months for subjects enrolled in Groups 1, 2, 3, and 4.
For infants, the duration of each participant's participation in the study will be approximately 16 to 19 months for subjects enrolled in Groups 5, 6, 7, and 8.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Toddlers and infants:
Specifically for toddlers:
Specifically for infants:
- Aged 42 to 89 days on the day of the first study visit
Exclusion criteria:
Toddlers and infants
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
One dose of SP0202-IIb and one dose of DTaP-IPV// Hib vaccine in toddlers aged 12-15 months who have previously received the 3-dose primary series of Prevnar13
Biological: Pneumococcal Conjugate Vaccine formulation 1 · Biological: Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus b Conjugate (Tetanus Toxoid Conjugate)
One dose of SP0202-VI and one dose of DTaP-IPV// Hib vaccine in toddlers aged 12-15 months who have previously received the 3-dose primary series of Prevnar13
Biological: Pneumococcal Conjugate Vaccine formulation 2 · Biological: Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus b Conjugate (Tetanus Toxoid Conjugate)
One dose of SP0202-VII and one dose of DTaP-IPV// Hib vaccine in toddlers aged 12-15 months who have previously received the 3-dose primary series of Prevnar13
Biological: Pneumococcal Conjugate Vaccine formulation 3 · Biological: Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus b Conjugate (Tetanus Toxoid Conjugate)
One dose of Prevnar 13 and one dose of DTaP-IPV// Hib vaccine in toddlers aged 12-15 months who have previously received the 3-dose primary series of Prevnar13
Biological: Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein] · Biological: Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus b Conjugate (Tetanus Toxoid Conjugate)
Four doses of SP0202-IIb at 2, 4, 6 and 12-15 months Routine pediatric vaccines: DTaP-IPV// Hib vaccine, rotavirus vaccine at 2, 4, 6 months; MMR vaccine and varicella vaccine at 12-15 months Hepatitis B vaccine at 2, 4, 6 months, as applicable
Biological: Pneumococcal Conjugate Vaccine formulation 1 · Biological: Varicella Virus Vaccine Live · Biological: Measles, Mumps, and Rubella Virus Vaccine Live · Biological: Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus b Conjugate (Tetanus Toxoid Conjugate) · Biological: Rotavirus Vaccine, Live, Oral, Pentavalent · Biological: Hepatitis B Vaccine* [Recombinant] *as applicable
Four doses of SP0202-VI at 2, 4, 6 and 12-15 months Routine pediatric vaccines: DTaP-IPV// Hib vaccine, rotavirus vaccine at 2, 4, 6 months; MMR vaccine and varicella vaccine at 12-15 months Hepatitis B vaccine at 2, 4, 6 months, as applicable
Biological: Pneumococcal Conjugate Vaccine formulation 2 · Biological: Varicella Virus Vaccine Live · Biological: Measles, Mumps, and Rubella Virus Vaccine Live · Biological: Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus b Conjugate (Tetanus Toxoid Conjugate) · Biological: Rotavirus Vaccine, Live, Oral, Pentavalent · Biological: Hepatitis B Vaccine* [Recombinant] *as applicable
Four doses of SP0202-VII at 2, 4, 6 and 12-15 months Routine pediatric vaccines: DTaP-IPV// Hib vaccine, rotavirus vaccine at 2, 4, 6 months; MMR vaccine and varicella vaccine at 12-15 months Hepatitis B vaccine at 2, 4, 6 months, as applicable
Biological: Pneumococcal Conjugate Vaccine formulation 3 · Biological: Varicella Virus Vaccine Live · Biological: Measles, Mumps, and Rubella Virus Vaccine Live · Biological: Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus b Conjugate (Tetanus Toxoid Conjugate) · Biological: Rotavirus Vaccine, Live, Oral, Pentavalent · Biological: Hepatitis B Vaccine* [Recombinant] *as applicable
Four doses of Prevnar 13 at 2, 4, 6 and 12-15 months Routine pediatric vaccines: DTaP-IPV// Hib vaccine, rotavirus vaccine at 2, 4, 6 months; MMR vaccine and varicella vaccine at 12-15 months Hepatitis B vaccine at 2, 4, 6 months, as applicable
Biological: Varicella Virus Vaccine Live · Biological: Measles, Mumps, and Rubella Virus Vaccine Live · Biological: Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein] · Biological: Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus b Conjugate (Tetanus Toxoid Conjugate) · Biological: Rotavirus Vaccine, Live, Oral, Pentavalent · Biological: Hepatitis B Vaccine* [Recombinant] *as applicable
Pharmaceutical form:liquid Route of administration: intramuscular
Also known as: SP0202-IIb
Pharmaceutical form:liquid Route of administration: intramuscular
Also known as: SP0202-VI
Pharmaceutical form:liquid Route of administration: intramuscular
Also known as: SP0202-VII
Pharmaceutical form:liquid Route of administration: subcutaneous
Also known as: Varicella vaccine, VARIVAX®
Pharmaceutical form:liquid Route of administration: subcutaneous
Also known as: MMR vaccine, M-M-R ®II
Pharmaceutical form:liquid Route of administration: intramuscular
Also known as: Prevnar 13®
Pharmaceutical form:liquid Route of administration: intramuscular
Also known as: DTaP-IPV// Hib vaccine, Pentacel®
Pharmaceutical form:liquid Route of administration: oral
Also known as: Rotavirus vaccine, RotaTeq
Pharmaceutical form:liquid Route of administration: intramuscular
Also known as: Hepatitis B vaccine, ENGERIX-B®
Number of Participants With Immediate Adverse Events (AEs)
An AE was any untoward medical occurrence in a participant or in a clinical investigation participant administered a medicinal product and which did not necessarily have a causal relationship with this treatment. Immediate events were recorded to capture medically relevant unsolicited systemic AEs (including those related to the product administered) that occurred within the first 30 minutes after vaccination. An unsolicited AE was an observed AE that did not fulfill the conditions prelisted in the case report book (CRB) in terms of diagnosis and/or onset window post-vaccination and included both serious adverse events (SAEs) and non-serious unsolicited AEs.
Time frame: Up to 30 minutes after each vaccination
Number of Participants With Solicited Injection Site Reactions
A solicited reaction was an "expected" adverse reaction (sign or symptom) observed and reported under the conditions (nature and onset) prelisted in the protocol and CRB and were considered to be related to the product administered. An injection site reaction was an adverse reaction at and around the injection site which were commonly inflammatory reactions. Solicited injection site reactions included tenderness, erythema and swelling around the injection site and were planned to be collected and reported for SP0202/Prevnar 13 for both toddlers and infants.
Time frame: Up to 7 days after each vaccination
Number of Participants With Solicited Systemic Reactions
A solicited reaction was an "expected" adverse reaction (sign or symptom) observed and reported under the conditions (nature and onset) pre-listed in the protocol and CRB and considered as related to the product administered. Solicited systemic reactions included fever, vomiting, abnormal crying, drowsiness, appetite loss, and irritability. Reported AEs for each arm were presented as pre-specified in protocol.
Time frame: Up to 7 days after each vaccination
Number of Participants With Unsolicited AEs
An AE was any untoward medical occurrence in a clinical investigation participant administered a medicinal product, and which did not necessarily have a causal relationship with this treatment. An unsolicited AE was an observed AE that did not fulfill the conditions prelisted in the CRB in terms of diagnosis and/or onset window post-vaccination. Unsolicited AEs included both SAEs and non-serious unsolicited AEs. Reported AEs for each arm were presented as pre-specified in protocol.
Time frame: Up to 30 days after each vaccination
Number of Participants With SAEs and Adverse Event of Special Interest (AESIs)
An SAE was any untoward medical occurrence that at any dose resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, or was an important medical event. An AESI (serious or non-serious) was defined as one of scientific and medical concern specific to the Sponsor's product or program, for which ongoing monitoring and rapid communication by the Investigator to the Sponsor was appropriate. The following AE were captured as AESI throughout the study: Anaphylaxis defined as per the Brighton collaboration case definition, convulsions including febrile convulsions, hypotonic-hyporesponsive episode and apnea. Reported AEs for each arm were presented as pre-specified in protocol.
Time frame: From first dose vaccine administration (Day 1) until 6 months after the last dose administration, 490 days
For Toddlers: Serotype Specific Immunoglobulin G (IgG) Geometric Mean Concentrations (GMCs) for Each Pneumococcal Serotype at 30 Days Post-Dose
The GMCs for serotype specific pneumococcal IgG antibodies were measured using pneumococcal capsular polysaccharide-electro-chemiluminescent assay (PnPS-ECL), a multiplexed serological assay which allows for the simultaneous quantification of human IgG against pneumococcal polysaccharide antigens.
Time frame: Day 30
For Infants: Percentage of Participants With Serotype Specific IgG Concentration >=0.35 mcg/mL 30 Days Post-Dose 3
Percentage of infants with serotype specific IgG concentration \>=0.35 mcg/mL for each pneumococcal serotype included in the SP0202 formulations were measured using ECL, a multiplexed serological assay which allows for the simultaneous quantification of human IgG against pneumococcal polysaccharide antigens.
Time frame: Day 150
For Infants: Serotype Specific IgG GMCs for Each Pneumococcal Serotype at 30 Days Post-Dose 3
The GMCs for serotype-specific pneumococcal IgG antibodies were measured using PnPS-ECL, a multiplexed serological assay which allows for the simultaneous quantification of human IgG against pneumococcal polysaccharide antigens.
Time frame: Day 150
For Infants: Serotype Specific IgG GMCs for Each Pneumococcal Serotype at 30 Days Post-Dose 4
The GMCs for serotype specific pneumococcal IgG antibodies were measured using PnPS-ECL, a multiplexed serological assay which allows for the simultaneous quantification of human IgG against pneumococcal polysaccharide antigens.
Time frame: Day 330
For Toddlers: Serotype Specific OPA Geometric Mean Titers (GMTs) for Each Pneumococcal Serotype 30 Days Post-Dose
The GMs for serotype specific OPA titers were measured using multiplex opsonophagocytic assay (MOPA) which is used to evaluate the opsonophagocytic index (50% killing) of pneumococcal anti-capsular polysaccharide antibodies in human serum samples following vaccination.
Time frame: Day 30
For Infants: Serotype Specific OPA GMTs for Each Pneumococcal Serotype 30 Days Post-Dose 3
The GMs for serotype specific OPA titers were measured using MOPA which is used to evaluate the opsonophagocytic index (50% killing) of pneumococcal anti-capsular polysaccharide antibodies in human serum samples following vaccination.
Time frame: Day 150
For Infants: Serotype Specific OPA GMTs for Each Pneumococcal Serotype 30 Days Post-Dose 4
The GMs for serotype specific OPA titers were measured using MOPA which is used to evaluate the opsonophagocytic index (50% killing) of pneumococcal anti-capsular polysaccharide antibodies in human serum samples following vaccination.
Time frame: Day 330
For Infants: GMC of Anti-Rotavirus Serum Immunoglobulin A (IgA) Antibodies 30 Days Post-Dose 3
Anti-rotavirus IgA antibodies in human serum were measured by enzyme linked immunosorbent assay (ELISA). A reference standard assayed on each plate was used to calculate the amount of specific anti-rotavirus IgA antibody in the units assigned by the reference standard.
Time frame: Day 150
For Infants: Percentage of Participants With Antibody Responses to Diphtheria, Tetanus and Polyribosylribitol Phosphate Antigens 30 Days Post-Dose 3
Percentage of participants with toxoid concentration \>=0.10 mcg/mL for diphtheria and tetanus and \>=0.15 mcg/mL for PRP are presented. Anti-diphtheria and anti-tetanus concentrations were measured using electro-chemiluminescence assay (ECL) and anti-PRP concentrations were measured using a Farr-type radioimmunoassay.
Time frame: Day 150
For Infants: Percentage of Participants With Antibody Responses to Poliovirus 1, 2 and 3 30 Days Post-Dose 3
Anti-poliovirus types 1, 2, and 3 were measured by neutralization assay. Response was defined as a titer \>=8.
Time frame: Day 150
For Infants: GMCs of Antibodies to Pertussis Antigens 30 Days Post-Dose 3
Serum samples were collected for analysis by ECL to determine the GMC of antibodies to the following Pertussis antigens: Pertussis toxoid/toxin, Filamentous hemagglutinin, Pertactin and Fimbriae types 2 and 3.
Time frame: Day 150
For Infants: Percentage of Participants With Antibody Responses to Hepatitis-B Antigens 30 Days Post-Dose 3
Anti-Hepatitis B antibodies were measured by the commercially available VITROS ECi/ECiQ immunodiagnostic system using chemiluminescence detection technology. The VITROS ECi immunodiagnostic system uses an antibody mediated antigen sandwich formation to detect the presence of anti-hepatitis B surface antigen total immunoglobulin in human serum. The threshold presented is \>=10 milli international units (mIU).
Time frame: Day 150
For Infants: Percentage of Participants With Antibody Responses to M-MRII and Varivax Antigens 30 Days Post-Dose 4
Anti-measles antibodies were determined by bulk measles IgG enzyme immunoassay (EIA); anti-mumps antibodies by ELISA, anti-rubella antibodies by bulk rubella IgG EIA and anti-varicella antibodies were determined by glycoprotein ELISA to detect total IgG antibody to respective virus before and after vaccination with a virus-containing vaccine. Percentage of participants with anti-measles antibody concentrations \>=255 mIU/mL, anti-mumps antibody concentrations: \>=10 antibody units/mL, anti-rubella antibody concentrations \>=10 IU/mL and anti-varicella concentrations \>=5 units/mL is reported in this outcome measure.
Time frame: Day 330
The Stage I of study was conducted at 22 active centers in the US between 22 May 2020 and 10 March 2021. The Stage II of study was conducted at 35 active centers in the US, Canada and Honduras between 16 April 2021 and 24 February 2022.
| Milestone | Stage I: Group 1 SP0202-IIb | Stage I: Group 2 SP0202-VI | Stage I: Group 3 SP0202-VII | Stage I: Group 4 Prevnar 13 | Stage II: Group 5 SP0202-IIb | Stage II: Group 6 SP0202-VI | Stage II: Group 7 SP0202-VII | Stage II: Group 8 Prevnar 13 |
|---|---|---|---|---|---|---|---|---|
| Started | 35 | 35 | 35 | 35 | 179 | 178 | 179 | 176 |
| Completed | 35 | 31 | 32 | 32 | 148 | 147 | 151 | 160 |
| Not completed | 0 | 4 | 3 | 3 | 31 | 31 | 28 | 16 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 |
| Withdrew: Lost to follow-up | 0 | 1 | 2 | 1 | 6 | 3 | 8 | 2 |
| Withdrew: Withdrawal by parent/guardian | 0 | 2 | 1 | 2 | 19 | 23 | 13 | 11 |
| Withdrew: Protocol deviation | 0 | 1 | 0 | 0 | 6 | 4 | 6 | 3 |
An AE was any untoward medical occurrence in a participant or in a clinical investigation participant administered a medicinal product and which did not necessarily have a causal relationship with this treatment. Immediate events were recorded to capture medically relevant unsolicited systemic AEs (including those related to the product administered) that occurred within the first 30 minutes after vaccination. An unsolicited AE was an observed AE that did not fulfill the conditions prelisted in the case report book (CRB) in terms of diagnosis and/or onset window post-vaccination and included both serious adverse events (SAEs) and non-serious unsolicited AEs.
| Participants | Stage I: Group 1 SP0202-IIb | Stage I: Group 2 SP0202-VI | Stage I: Group 3 SP0202-VII | Stage I: Group 4 Prevnar 13 | Stage II: Group 5 SP0202-IIb | Stage II: Group 6 SP0202-VI | Stage II: Group 7 SP0202-VII | Stage II: Group 8 Prevnar 13 |
|---|---|---|---|---|---|---|---|---|
| Number of Participants With Immediate Adverse Events (AEs) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
A solicited reaction was an "expected" adverse reaction (sign or symptom) observed and reported under the conditions (nature and onset) prelisted in the protocol and CRB and were considered to be related to the product administered. An injection site reaction was an adverse reaction at and around the injection site which were commonly inflammatory reactions. Solicited injection site reactions included tenderness, erythema and swelling around the injection site and were planned to be collected and reported for SP0202/Prevnar 13 for both toddlers and infants.
| Participants | Stage I: Group 1 SP0202-IIb | Stage I: Group 2 SP0202-VI | Stage I: Group 3 SP0202-VII | Stage I: Group 4 Prevnar 13 | Stage II: Group 5 SP0202-IIb | Stage II: Group 6 SP0202-VI | Stage II: Group 7 SP0202-VII | Stage II: Group 8 Prevnar 13 |
|---|---|---|---|---|---|---|---|---|
| Number of Participants With Solicited Injection Site Reactions | 21 | 18 | 21 | 13 | 119 | 128 | 126 | 124 |
A solicited reaction was an "expected" adverse reaction (sign or symptom) observed and reported under the conditions (nature and onset) pre-listed in the protocol and CRB and considered as related to the product administered. Solicited systemic reactions included fever, vomiting, abnormal crying, drowsiness, appetite loss, and irritability. Reported AEs for each arm were presented as pre-specified in protocol.
| Participants | Stage I: Group 1 SP0202-IIb | Stage I: Group 2 SP0202-VI | Stage I: Group 3 SP0202-VII | Stage I: Group 4 Prevnar 13 | Stage II: Group 5 SP0202-IIb | Stage II: Group 6 SP0202-VI | Stage II: Group 7 SP0202-VII | Stage II: Group 8 Prevnar 13 |
|---|---|---|---|---|---|---|---|---|
| Number of Participants With Solicited Systemic Reactions | 25 | 23 | 27 | 24 | 139 | 143 | 137 | 138 |
An AE was any untoward medical occurrence in a clinical investigation participant administered a medicinal product, and which did not necessarily have a causal relationship with this treatment. An unsolicited AE was an observed AE that did not fulfill the conditions prelisted in the CRB in terms of diagnosis and/or onset window post-vaccination. Unsolicited AEs included both SAEs and non-serious unsolicited AEs. Reported AEs for each arm were presented as pre-specified in protocol.
| Participants | Stage I: Group 1 SP0202-IIb | Stage I: Group 2 SP0202-VI | Stage I: Group 3 SP0202-VII | Stage I: Group 4 Prevnar 13 | Stage II: Group 5 SP0202-IIb | Stage II: Group 6 SP0202-VI | Stage II: Group 7 SP0202-VII | Stage II: Group 8 Prevnar 13 |
|---|---|---|---|---|---|---|---|---|
| Number of Participants With Unsolicited AEs | 7 | 3 | 4 | 6 | 122 | 116 | 118 | 117 |
An SAE was any untoward medical occurrence that at any dose resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, or was an important medical event. An AESI (serious or non-serious) was defined as one of scientific and medical concern specific to the Sponsor's product or program, for which ongoing monitoring and rapid communication by the Investigator to the Sponsor was appropriate. The following AE were captured as AESI throughout the study: Anaphylaxis defined as per the Brighton collaboration case definition, convulsions including febrile convulsions, hypotonic-hyporesponsive episode and apnea. Reported AEs for each arm were presented as pre-specified in protocol.
| Participants | Stage I: Group 1 SP0202-IIb | Stage I: Group 2 SP0202-VI | Stage I: Group 3 SP0202-VII | Stage I: Group 4 Prevnar 13 | Stage II: Group 5 SP0202-IIb | Stage II: Group 6 SP0202-VI | Stage II: Group 7 SP0202-VII | Stage II: Group 8 Prevnar 13 |
|---|---|---|---|---|---|---|---|---|
| Any SAEs | 0 | 1 | 0 | 0 | 3 | 9 | 8 | 9 |
| Any AESIs | 1 | 0 | 0 | 0 | 1 | 1 | 1 | 0 |
The GMCs for serotype specific pneumococcal IgG antibodies were measured using pneumococcal capsular polysaccharide-electro-chemiluminescent assay (PnPS-ECL), a multiplexed serological assay which allows for the simultaneous quantification of human IgG against pneumococcal polysaccharide antigens.
| microgram/millilitre (mcg/mL) | Stage I: Group 1 SP0202-IIb | Stage I: Group 2 SP0202-VI | Stage I: Group 3 SP0202-VII | Stage I: Group 4 Prevnar 13 |
|---|---|---|---|---|
| Serotype 1 | 2.46 (1.59 to 3.82) | 2.12 (1.40 to 3.21) | 3.29 (2.55 to 4.24) | 3.80 (2.76 to 5.24) |
| Serotype 3 | 0.766 (0.569 to 1.03) | 0.973 (0.748 to 1.26) | 1.16 (0.963 to 1.40) | 0.835 (0.629 to 1.11) |
| Serotype 4 | 1.53 (1.07 to 2.19) | 1.51 (1.10 to 2.08) | 2.27 (1.58 to 3.27) | 1.73 (1.32 to 2.25) |
| Serotype 5 | 2.44 (1.74 to 3.42) | 2.38 (1.66 to 3.42) | 2.80 (2.00 to 3.93) | 2.69 (2.02 to 3.58) |
| Serotype 6A | 7.53 (5.48 to 10.4) | 5.87 (4.20 to 8.20) | 8.29 (6.51 to 10.6) | 8.54 (6.44 to 11.3) |
| Serotype 6B | 5.21 (3.67 to 7.40) | 4.16 (3.15 to 5.50) | 7.11 (5.21 to 9.70) | 5.77 (4.33 to 7.70) |
| Serotype 7F | 2.99 (2.32 to 3.86) | 3.23 (2.37 to 4.41) | 2.91 (2.23 to 3.80) | 3.80 (3.06 to 4.73) |
| Serotype 9V | 3.25 (2.47 to 4.27) | 2.99 (2.22 to 4.01) | 5.27 (3.99 to 6.97) | 3.13 (2.31 to 4.24) |
| Serotype 14 | 7.37 (5.39 to 10.1) | 6.54 (4.62 to 9.27) | 5.75 (4.48 to 7.38) | 9.83 (7.65 to 12.6) |
| Serotype 18C | 1.80 (1.25 to 2.59) | 2.23 (1.57 to 3.19) | 2.19 (1.67 to 2.87) | 2.53 (1.99 to 3.21) |
| Serotype 19A | 3.67 (2.56 to 5.26) | 5.41 (3.62 to 8.08) | 5.45 (4.17 to 7.11) | 6.20 (4.83 to 7.96) |
| Serotype 19F | 3.88 (2.77 to 5.42) | 4.12 (2.99 to 5.70) | 5.79 (4.02 to 8.35) | 6.50 (4.69 to 9.02) |
| Serotype 23F | 2.42 (1.71 to 3.43) | 2.65 (1.98 to 3.55) | 3.64 (2.75 to 4.82) | 3.02 (2.11 to 4.32) |
| Serotype 8 | 6.86 (4.96 to 9.50) | 4.91 (3.74 to 6.44) | 7.11 (5.17 to 9.80) | 0.235 (0.158 to 0.350) |
| Serotype 9N | 3.46 (2.21 to 5.43) | 2.02 (1.43 to 2.84) | 2.78 (2.04 to 3.79) | 0.668 (0.437 to 1.02) |
| Serotype 10A | 1.84 (1.18 to 2.87) | 1.05 (0.669 to 1.66) | 1.48 (0.988 to 2.21) | 0.244 (0.180 to 0.331) |
| Serotype 11A | 4.41 (3.25 to 5.99) | 3.20 (2.48 to 4.13) | 4.61 (3.34 to 6.35) | 0.188 (0.144 to 0.247) |
| Serotype 12F | 0.767 (0.454 to 1.29) | 0.778 (0.541 to 1.12) | 0.907 (0.596 to 1.38) | 0.094 (0.078 to 0.112) |
| Serotype 15B | 0.680 (0.447 to 1.03) | 0.560 (0.370 to 0.848) | 0.644 (0.425 to 0.974) | 0.172 (0.122 to 0.241) |
| Serotype 22F | 4.43 (3.12 to 6.30) | 4.26 (2.66 to 6.82) | 5.20 (3.51 to 7.69) | 0.178 (0.122 to 0.259) |
| Serotype 33F | 1.26 (0.694 to 2.29) | 1.13 (0.771 to 1.65) | 1.75 (1.09 to 2.79) | 0.256 (0.189 to 0.345) |
Percentage of infants with serotype specific IgG concentration \>=0.35 mcg/mL for each pneumococcal serotype included in the SP0202 formulations were measured using ECL, a multiplexed serological assay which allows for the simultaneous quantification of human IgG against pneumococcal polysaccharide antigens.
| percentage of participants | Stage II: Group 5 SP0202-IIb | Stage II: Group 6 SP0202-VI | Stage II: Group 7 SP0202-VII | Stage II: Group 8 Prevnar 13 |
|---|---|---|---|---|
| Serotype 1 | 97.7 (93.5 to 99.5) | 96.7 (91.8 to 99.1) | 95.2 (89.8 to 98.2) | 97.0 (92.4 to 99.2) |
| Serotype 3 | 94.7 (89.5 to 97.9) | 95.1 (89.6 to 98.2) | 97.6 (93.1 to 99.5) | 81.8 (74.2 to 88.0) |
| Serotype 4 | 97.0 (92.5 to 99.2) | 95.9 (90.7 to 98.7) | 97.6 (93.1 to 99.5) | 97.7 (93.5 to 99.5) |
| Serotype 5 | 98.5 (94.7 to 99.8) | 96.7 (91.8 to 99.1) | 93.6 (87.8 to 97.2) | 97.0 (92.4 to 99.2) |
| Serotype 6A | 99.2 (95.9 to 100) | 96.7 (91.8 to 99.1) | 99.2 (95.6 to 100) | 99.2 (95.9 to 100) |
| Serotype 6B | 85.7 (78.6 to 91.2) | 81.1 (73.1 to 87.7) | 84.0 (76.4 to 89.9) | 97.0 (92.4 to 99.2) |
| Serotype 7F | 100 (97.3 to 100) | 100 (97.0 to 100) | 99.2 (95.6 to 100) | 100 (97.2 to 100) |
| Serotype 9V | 96.2 (91.4 to 98.8) | 89.3 (82.5 to 94.2) | 94.4 (88.8 to 97.7) | 99.2 (95.9 to 100) |
| Serotype 14 | 99.2 (95.9 to 100) | 99.2 (95.5 to 100) | 97.6 (93.1 to 99.5) | 96.9 (92.4 to 99.2) |
| Serotype 18C | 97.0 (92.5 to 99.2) | 97.5 (93.0 to 99.5) | 97.6 (93.1 to 99.5) | 96.2 (91.4 to 98.8) |
| Serotype 19A | 94.0 (88.5 to 97.4) | 93.4 (87.5 to 97.1) | 96.0 (90.9 to 98.7) | 97.0 (92.4 to 99.2) |
| Serotype 19F | 100 (97.3 to 100) | 99.2 (95.5 to 100) | 96.8 (92.0 to 99.1) | 99.2 (95.8 to 100) |
| Serotype 23F | 97.7 (93.5 to 99.5) | 96.7 (91.8 to 99.1) | 96.0 (90.9 to 98.7) | 93.9 (88.4 to 97.3) |
| Serotype 8 | 99.2 (95.9 to 100) | 100 (97.0 to 100) | 99.2 (95.6 to 100) | 9.2 (4.8 to 15.5) |
| Serotype 9N | 99.2 (95.9 to 100) | 98.4 (94.2 to 99.8) | 98.4 (94.3 to 99.8) | 65.9 (57.2 to 73.9) |
| Serotype 10A | 93.2 (87.5 to 96.9) | 92.6 (86.5 to 96.6) | 96.0 (90.9 to 98.7) | 3.8 (1.2 to 8.6) |
| Serotype 11A | 98.5 (94.7 to 99.8) | 100 (97.0 to 100) | 97.6 (93.1 to 99.5) | 7.6 (3.7 to 13.5) |
| Serotype 12F | 97.7 (93.5 to 99.5) | 93.4 (87.5 to 97.1) | 94.4 (88.8 to 97.7) | 0 (0 to 2.8) |
| Serotype 15B | 98.5 (94.7 to 99.8) | 95.9 (90.7 to 98.7) | 97.6 (93.1 to 99.5) | 6.9 (3.2 to 12.6) |
| Serotype 22F | 100 (97.3 to 100) | 97.5 (93.0 to 99.5) | 97.6 (93.1 to 99.5) | 3.0 (0.8 to 7.6) |
| Serotype 33F | 91.7 (85.7 to 95.8) | 89.3 (82.5 to 94.2) | 92.8 (86.8 to 96.7) | 3.8 (1.3 to 8.7) |
The GMCs for serotype-specific pneumococcal IgG antibodies were measured using PnPS-ECL, a multiplexed serological assay which allows for the simultaneous quantification of human IgG against pneumococcal polysaccharide antigens.
| mcg/mL | Stage II: Group 5 SP0202-IIb | Stage II: Group 6 SP0202-VI | Stage II: Group 7 SP0202-VII | Stage II: Group 8 Prevnar 13 |
|---|---|---|---|---|
| Serotype 1 | 1.91 (1.66 to 2.19) | 2.21 (1.88 to 2.61) | 1.97 (1.66 to 2.34) | 2.81 (2.39 to 3.30) |
| Serotype 3 | 0.800 (0.721 to 0.887) | 1.14 (1.01 to 1.27) | 1.17 (1.04 to 1.31) | 0.676 (0.598 to 0.764) |
| Serotype 4 | 0.900 (0.819 to 0.988) | 0.880 (0.798 to 0.971) | 1.06 (0.951 to 1.18) | 1.63 (1.45 to 1.83) |
| Serotype 5 | 3.62 (3.02 to 4.35) | 3.26 (2.70 to 3.95) | 3.00 (2.42 to 3.71) | 1.88 (1.63 to 2.17) |
| Serotype 6A | 3.41 (2.93 to 3.96) | 2.77 (2.33 to 3.30) | 3.26 (2.78 to 3.82) | 4.53 (3.93 to 5.21) |
| Serotype 6B | 1.95 (1.52 to 2.49) | 1.64 (1.22 to 2.20) | 1.97 (1.51 to 2.59) | 2.87 (2.36 to 3.48) |
| Serotype 7F | 3.88 (3.47 to 4.34) | 3.68 (3.27 to 4.14) | 3.45 (3.05 to 3.90) | 3.93 (3.53 to 4.36) |
| Serotype 9V | 1.35 (1.18 to 1.55) | 1.16 (0.989 to 1.37) | 1.49 (1.27 to 1.74) | 2.41 (2.12 to 2.74) |
| Serotype 14 | 7.49 (6.36 to 8.81) | 6.83 (5.85 to 7.98) | 6.84 (5.73 to 8.17) | 7.41 (6.20 to 8.86) |
| Serotype 18C | 1.67 (1.49 to 1.87) | 1.56 (1.391 to 1.76) | 1.46 (1.31 to 1.63) | 1.92 (1.67 to 2.20) |
| Serotype 19A | 1.86 (1.57 to 2.20) | 1.74 (1.43 to 2.11) | 1.86 (1.57 to 2.21) | 2.17 (1.85 to 2.54) |
| Serotype 19F | 3.32 (2.98 to 3.70) | 3.31 (2.93 to 3.75) | 2.95 (2.51 to 3.46) | 3.70 (3.23 to 4.24) |
| Serotype 23F | 2.69 (2.31 to 3.13) | 1.96 (1.69 to 2.28) | 2.05 (1.73 to 2.43) | 1.71 (1.44 to 2.04) |
| Serotype 8 | 3.27 (2.92 to 3.66) | 2.87 (2.55 to 3.22) | 3.08 (2.70 to 3.51) | 0.105 (0.093 to 0.119) |
| Serotype 9N | 2.53 (2.26 to 2.84) | 2.39 (2.10 to 2.71) | 2.42 (2.12 to 2.77) | 0.510 (0.424 to 0.612) |
| Serotype 10A | 2.86 (2.29 to 3.57) | 2.84 (2.24 to 3.59) | 3.26 (2.68 to 3.97) | 0.098 (0.089 to 0.108) |
| Serotype 11A | 2.52 (2.21 to 2.88) | 2.51 (2.21 to 2.85) | 2.32 (1.99 to 2.71) | 0.108 (0.095 to 0.123) |
| Serotype 12F | 1.93 (1.68 to 2.23) | 1.56 (1.33 to 1.82) | 1.54 (1.31 to 1.81) | 0.076 (0.075 to 0.078) |
| Serotype 15B | 7.88 (6.54 to 9.48) | 7.161 (5.73 to 8.95) | 6.84 (5.54 to 8.45) | 0.097 (0.087 to 0.107) |
| Serotype 22F | 12.3 (10.8 to 14.1) | 10.4 (8.59 to 12.6) | 9.27 (7.58 to 11.3) | 0.092 (0.083 to 0.103) |
| Serotype 33F | 2.67 (2.11 to 3.37) | 2.61 (2.05 to 3.32) | 2.57 (2.09 to 3.16) | 0.093 (0.085 to 0.101) |
The GMCs for serotype specific pneumococcal IgG antibodies were measured using PnPS-ECL, a multiplexed serological assay which allows for the simultaneous quantification of human IgG against pneumococcal polysaccharide antigens.
| mcg/mL | Stage II: Group 5 SP0202-IIb | Stage II: Group 6 SP0202-VI | Stage II: Group 7 SP0202-VII | Stage II: Group 8 Prevnar 13 |
|---|---|---|---|---|
| Serotype 1 | 3.16 (2.68 to 3.73) | 3.59 (3.02 to 4.26) | 3.44 (2.87 to 4.12) | 3.89 (3.35 to 4.50) |
| Serotype 3 | 0.755 (0.675 to 0.844) | 1.07 (0.949 to 1.21) | 1.03 (0.922 to 1.16) | 0.961 (0.843 to 1.09) |
| Serotype 4 | 1.37 (1.18 to 1.59) | 1.25 (1.08 to 1.45) | 1.75 (1.49 to 2.05) | 2.41 (2.09 to 2.77) |
| Serotype 5 | 7.56 (6.24 to 9.18) | 6.46 (5.25 to 7.95) | 6.63 (5.32 to 8.24) | 3.07 (2.67 to 3.54) |
| Serotype 6A | 9.44 (8.01 to 11.1) | 8.08 (6.93 to 9.43) | 7.80 (6.50 to 9.36) | 10.8 (9.36 to 12.4) |
| Serotype 6B | 8.77 (7.14 to 10.8) | 8.36 (6.88 to 10.2) | 7.96 (6.63 to 9.57) | 8.54 (7.46 to 9.78) |
| Serotype 7F | 4.42 (3.93 to 4.97) | 4.19 (3.63 to 4.85) | 3.76 (3.33 to 4.24) | 5.41 (4.80 to 6.09) |
| Serotype 9V | 2.20 (1.89 to 2.57) | 2.06 (1.78 to 2.38) | 2.57 (2.20 to 3.01) | 4.32 (3.77 to 4.95) |
| Serotype 14 | 6.94 (5.93 to 8.11) | 6.77 (5.62 to 8.14) | 7.70 (6.58 to 9.00) | 8.73 (7.34 to 10.4) |
| Serotype 18C | 1.79 (1.58 to 2.02) | 1.66 (1.46 to 1.90) | 1.55 (1.37 to 1.77) | 2.81 (2.46 to 3.21) |
| Serotype 19A | 6.92 (5.79 to 8.28) | 7.36 (6.12 to 8.84) | 7.72 (6.37 to 9.36) | 7.38 (6.28 to 8.67) |
| Serotype 19F | 6.64 (5.75 to 7.67) | 7.48 (6.18 to 9.06) | 6.68 (5.62 to 7.94) | 7.03 (6.05 to 8.16) |
| Serotype 23F | 3.78 (3.19 to 4.49) | 2.90 (2.46 to 3.42) | 2.99 (2.50 to 3.57) | 3.54 (3.02 to 4.16) |
| Serotype 8 | 4.64 (3.94 to 5.46) | 4.36 (3.74 to 5.08) | 4.26 (3.56 to 5.10) | 0.238 (0.196 to 0.289) |
| Serotype 9N | 4.16 (3.60 to 4.79) | 4.23 (3.72 to 4.80) | 3.80 (3.18 to 4.54) | 0.953 (0.773 to 1.18) |
| Serotype 10A | 5.67 (4.71 to 6.83) | 5.70 (4.76 to 6.83) | 4.78 (3.96 to 5.78) | 0.160 (0.137 to 0.187) |
| Serotype 11A | 3.66 (3.17 to 4.21) | 3.92 (3.36 to 4.57) | 3.22 (2.69 to 3.85) | 0.154 (0.128 to 0.186) |
| Serotype 12F | 2.68 (2.30 to 3.13) | 2.25 (1.94 to 2.61) | 2.04 (1.73 to 2.41) | 0.080 (0.076 to 0.085) |
| Serotype 15B | 19.6 (16.5 to 23.2) | 17.3 (14.2 to 21.2) | 15.7 (12.6 to 19.5) | 0.114 (0.097 to 0.134) |
| Serotype 22F | 24.5 (21.1 to 28.3) | 21.3 (17.8 to 25.6) | 20.6 (16.8 to 25.2) | 0.173 (0.144 to 0.206) |
| Serotype 33F | 4.74 (4.07 to 5.52) | 4.83 (4.13 to 5.65) | 4.62 (3.89 to 5.49) | 0.158 (0.134 to 0.186) |
The GMs for serotype specific OPA titers were measured using multiplex opsonophagocytic assay (MOPA) which is used to evaluate the opsonophagocytic index (50% killing) of pneumococcal anti-capsular polysaccharide antibodies in human serum samples following vaccination.
| 1/dilution (1/dil) | Stage I: Group 1 SP0202-IIb | Stage I: Group 2 SP0202-VI | Stage I: Group 3 SP0202-VII | Stage I: Group 4 Prevnar 13 |
|---|---|---|---|---|
| Serotype 1 | 138 (62.1 to 306) | 94.2 (49.9 to 178) | 177 (92.3 to 339) | 247 (140 to 434) |
| Serotype 3 | 272 (204 to 363) | 314 (229 to 431) | 393 (287 to 537) | 216 (160 to 292) |
| Serotype 4 | 3467 (2296 to 5234) | 2862 (2027 to 4041) | 5420 (3366 to 8725) | 2975 (1981 to 4466) |
| Serotype 5 | 1287 (736 to 2252) | 1333 (867 to 2050) | 1397 (817 to 2389) | 1307 (820 to 2082) |
| Serotype 6A | 4623 (3110 to 6871) | 6083 (4341 to 8523) | 7232 (5071 to 10315) | 7553 (5386 to 10592) |
| Serotype 6B | 3027 (1935 to 4737) | 3542 (2348 to 5342) | 5171 (3369 to 7935) | 4679 (3132 to 6992) |
| Serotype 7F | 8449 (5127 to 13924) | 7640 (4974 to 11734) | 6284 (4099 to 9634) | 10443 (6580 to 16575) |
| Serotype 9V | 3612 (2492 to 5236) | 3254 (2121 to 4991) | 4720 (2911 to 7654) | 4057 (2778 to 5926) |
| Serotype 14 | 3598 (2195 to 5898) | 3881 (2534 to 5943) | 3191 (2045 to 4979) | 2828 (1948 to 4107) |
| Serotype 18C | 1490 (921 to 2411) | 1760 (1176 to 2634) | 1722 (1233 to 2404) | 2424 (1558 to 3771) |
| Serotype 19A | 3082 (2115 to 4493) | 3174 (2302 to 4377) | 3004 (2121 to 4256) | 5354 (3343 to 8577) |
| Serotype 19F | 1194 (838 to 1701) | 1806 (1207 to 2702) | 1569 (955 to 2576) | 2554 (1818 to 3588) |
| Serotype 23F | 5451 (3431 to 8662) | 7457 (5131 to 10838) | 5179 (3303 to 8121) | 9264 (5738 to 14957) |
| Serotype 8 | 4244 (2705 to 6658) | 7003 (5065 to 9681) | 7989 (5076 to 12576) | 222 (120 to 412) |
| Serotype 9N | 11562 (9510 to 14057) | 8391 (6117 to 11511) | 12115 (8129 to 18054) | 2061 (1445 to 2940) |
| Serotype 10A | 3582 (2518 to 5096) | 3615 (2706 to 4829) | 4001 (2768 to 5782) | 10.0 (4.07 to 24.7) |
| Serotype 11A | 611 (378 to 988) | 686 (349 to 1345) | 661 (311 to 1408) | 4.14 (3.86 to 4.44) |
| Serotype 12F | 6767 (4628 to 9895) | 7391 (4704 to 11615) | 7955 (4793 to 13205) | 5.27 (3.28 to 8.46) |
| Serotype 15B | 1087 (402 to 2941) | 1346 (496 to 3658) | 1476 (467 to 4671) | 37.7 (20.3 to 69.8) |
| Serotype 22F | 4106 (2963 to 5690) | 3352 (2354 to 4773) | 4443 (2858 to 6906) | 69.0 (24.3 to 196) |
| Serotype 33F | 39691 (27999 to 56266) | 30399 (18394 to 50238) | 35326 (24106 to 51770) | 2689 (1702 to 4249) |
The GMs for serotype specific OPA titers were measured using MOPA which is used to evaluate the opsonophagocytic index (50% killing) of pneumococcal anti-capsular polysaccharide antibodies in human serum samples following vaccination.
| 1/dil | Stage II: Group 5 SP0202-IIb | Stage II: Group 6 SP0202-VI | Stage II: Group 7 SP0202-VII | Stage II: Group 8 Prevnar 13 |
|---|---|---|---|---|
| Serotype 1 | 73.6 (53.4 to 101) | 81.7 (59.1 to 113) | 66.4 (46.7 to 94.5) | 114 (86.4 to 151) |
| Serotype 3 | 170 (146 to 197) | 218 (180 to 266) | 260 (226 to 300) | 178 (147 to 215) |
| Serotype 4 | 703 (586 to 843) | 616 (492 to 771) | 1154 (934 to 1425) | 1789 (1489 to 2151) |
| Serotype 5 | 602 (469 to 771) | 492 (372 to 652) | 495 (370 to 662) | 569 (450 to 719) |
| Serotype 6A | 2456 (2032 to 2969) | 2223 (1743 to 2834) | 2664 (2187 to 3245) | 2799 (2307 to 3395) |
| Serotype 6B | 1436 (1008 to 2045) | 1041 (677 to 1602) | 1885 (1384 to 2567) | 2472 (1934 to 3160) |
| Serotype 7F | 5964 (4989 to 7130) | 5449 (4536 to 6545) | 5889 (4980 to 6963) | 5252 (4521 to 6102) |
| Serotype 9V | 898 (659 to 1224) | 700 (483 to 1014) | 1136 (866 to 1492) | 1319 (1040 to 1672) |
| Serotype 14 | 1959 (1580 to 2429) | 1767 (1391 to 2244) | 2293 (1858 to 2829) | 1920 (1574 to 2344) |
| Serotype 18C | 866 (731 to 1026) | 819 (668 to 1003) | 804 (660 to 979) | 1000 (804 to 1245) |
| Serotype 19A | 640 (521 to 788) | 512 (384 to 684) | 778 (630 to 962) | 1130 (959 to 1332) |
| Serotype 19F | 533 (422 to 674) | 591 (451 to 774) | 629 (461 to 860) | 613 (489 to 768) |
| Serotype 23F | 2654 (2157 to 3265) | 1967 (1500 to 2580) | 2279 (1770 to 2934) | 4299 (3536 to 5227) |
| Serotype 8 | 1486 (1239 to 1782) | 1440 (1237 to 1677) | 1612 (1378 to 1886) | 133 (89.9 to 196) |
| Serotype 9N | 4261 (3534 to 5138) | 4994 (4248 to 5870) | 5257 (4150 to 6661) | 811 (585 to 1126) |
| Serotype 10A | 2306 (1539 to 3453) | 2722 (1875 to 3951) | 3251 (2501 to 4225) | 9.42 (6.33 to 14.0) |
| Serotype 11A | 52.6 (36.7 to 75.3) | 64.9 (44.2 to 95.3) | 76.6 (52.6 to 112) | 5.91 (4.62 to 7.54) |
| Serotype 12F | 2182 (1764 to 2700) | 2179 (1798 to 2640) | 2334 (1836 to 2967) | 5.31 (4.15 to 6.80) |
| Serotype 15B | 6686 (5281 to 8466) | 5859 (4218 to 8139) | 5220 (3829 to 7116) | 28.1 (22.8 to 34.7) |
| Serotype 22F | 5227 (4421 to 6181) | 4657 (3802 to 5706) | 4617 (3725 to 5723) | 16.1 (12.5 to 20.7) |
| Serotype 33F | 10070 (7198 to 14088) | 11179 (8604 to 14524) | 11900 (8552 to 16559) | 311 (181 to 535) |
The GMs for serotype specific OPA titers were measured using MOPA which is used to evaluate the opsonophagocytic index (50% killing) of pneumococcal anti-capsular polysaccharide antibodies in human serum samples following vaccination.
| 1/dil | Stage II: Group 5 SP0202-IIb | Stage II: Group 6 SP0202-VI | Stage II: Group 7 SP0202-VII | Stage II: Group 8 Prevnar 13 |
|---|---|---|---|---|
| Serotype 1 | 407 (295 to 561) | 355 (255 to 495) | 320 (211 to 486) | 318 (251 to 403) |
| Serotype 3 | 274 (230 to 328) | 308 (244 to 390) | 376 (314 to 450) | 348 (294 to 412) |
| Serotype 4 | 3754 (3002 to 4694) | 2536 (1915 to 3359) | 5556 (4318 to 7150) | 6028 (4801 to 7570) |
| Serotype 5 | 2348 (1884 to 2926) | 1787 (1365 to 2339) | 2131 (1626 to 2794) | 1396 (1119 to 1740) |
| Serotype 6A | 5153 (4338 to 6119) | 4786 (3929 to 5829) | 4433 (3434 to 5722) | 6862 (5741 to 8202) |
| Serotype 6B | 3899 (3019 to 5037) | 3305 (2614 to 4178) | 3638 (2756 to 4802) | 7092 (5699 to 8825) |
| Serotype 7F | 10234 (8469 to 12368) | 8643 (7263 to 10285) | 9232 (7448 to 11444) | 13971 (11575 to 16863) |
| Serotype 9V | 3044 (2424 to 3823) | 2641 (2137 to 3263) | 2956 (2363 to 3698) | 4364 (3459 to 5505) |
| Serotype 14 | 3415 (2785 to 4188) | 3098 (2527 to 3798) | 4190 (3397 to 5168) | 3378 (2559 to 4459) |
| Serotype 18C | 1891 (1565 to 2285) | 1422 (1110 to 1823) | 1368 (1092 to 1713) | 2821 (2342 to 3399) |
| Serotype 19A | 3808 (3057 to 4743) | 3086 (2422 to 3933) | 3580 (2806 to 4566) | 7535 (6068 to 9357) |
| Serotype 19F | 2071 (1730 to 2481) | 1821 (1313 to 2527) | 1654 (1173 to 2332) | 2249 (1750 to 2889) |
| Serotype 23F | 5444 (4211 to 7037) | 4444 (3644 to 5418) | 4047 (3019 to 5424) | 18569 (14765 to 23352) |
| Serotype 8 | 4559 (3753 to 5537) | 4229 (3527 to 5070) | 4916 (3751 to 6443) | 773 (616 to 970) |
| Serotype 9N | 9479 (7967 to 11277) | 8565 (7485 to 9800) | 10257 (8771 to 11995) | 3043 (2370 to 3906) |
| Serotype 10A | 4278 (3125 to 5856) | 4797 (3722 to 6184) | 4768 (3358 to 6770) | 46.6 (23.9 to 90.9) |
| Serotype 11A | 433 (310 to 604) | 390 (253 to 603) | 550 (372 to 812) | 8.11 (5.45 to 12.1) |
| Serotype 12F | 4520 (3743 to 5459) | 4757 (3800 to 5956) | 5030 (3785 to 6685) | 7.92 (5.26 to 12.0) |
| Serotype 15B | 14756 (11612 to 18750) | 13136 (9623 to 17932) | 12799 (9111 to 17981) | 55.2 (36.7 to 83.0) |
| Serotype 22F | 20372 (15640 to 26536) | 16063 (12306 to 20967) | 21319 (15648 to 29045) | 65.7 (37.7 to 114) |
| Serotype 33F | 26134 (20845 to 32766) | 21202 (17071 to 26332) | 32376 (25782 to 40657) | 3224 (2388 to 4353) |
Anti-rotavirus IgA antibodies in human serum were measured by enzyme linked immunosorbent assay (ELISA). A reference standard assayed on each plate was used to calculate the amount of specific anti-rotavirus IgA antibody in the units assigned by the reference standard.
| Units (U)/mL | Stage II: Group 5 SP0202-IIb | Stage II: Group 6 SP0202-VI | Stage II: Group 7 SP0202-VII | Stage II: Group 8 Prevnar 13 |
|---|---|---|---|---|
| For Infants: GMC of Anti-Rotavirus Serum Immunoglobulin A (IgA) Antibodies 30 Days Post-Dose 3 | 407 (303 to 545) | 390 (283 to 537) | 494 (369 to 661) | 393 (277 to 560) |
Percentage of participants with toxoid concentration \>=0.10 mcg/mL for diphtheria and tetanus and \>=0.15 mcg/mL for PRP are presented. Anti-diphtheria and anti-tetanus concentrations were measured using electro-chemiluminescence assay (ECL) and anti-PRP concentrations were measured using a Farr-type radioimmunoassay.
| percentage of participants | Stage II: Group 5 SP0202-IIb | Stage II: Group 6 SP0202-VI | Stage II: Group 7 SP0202-VII | Stage II: Group 8 Prevnar 13 |
|---|---|---|---|---|
| Anti-Diphtheria toxoid | 94.6 (89.2 to 97.8) | 97.5 (92.7 to 99.5) | 95.9 (90.8 to 98.7) | 96.9 (92.3 to 99.2) |
| Anti-Tetanus toxoid | 100 (97.2 to 100) | 100 (96.9 to 100) | 100 (97.0 to 100) | 100 (97.2 to 100) |
| Anti-PRP | 99.2 (95.7 to 100) | 99.1 (95.2 to 100) | 98.2 (93.7 to 99.8) | 100 (97.2 to 100) |
Anti-poliovirus types 1, 2, and 3 were measured by neutralization assay. Response was defined as a titer \>=8.
| percentage of participants | Stage II: Group 5 SP0202-IIb | Stage II: Group 6 SP0202-VI | Stage II: Group 7 SP0202-VII | Stage II: Group 8 Prevnar 13 |
|---|---|---|---|---|
| Anti-poliovirus 1 | 99.2 (95.6 to 100) | 100 (96.7 to 100) | 97.4 (92.5 to 99.5) | 100 (97.1 to 100) |
| Anti-poliovirus 2 | 100 (97.0 to 100) | 100 (96.5 to 100) | 99.1 (95.1 to 100) | 100 (97.1 to 100) |
| Anti-poliovirus 3 | 100 (97.1 to 100) | 100 (96.7 to 100) | 99.1 (95.1 to 100) | 100 (97.1 to 100) |
Serum samples were collected for analysis by ECL to determine the GMC of antibodies to the following Pertussis antigens: Pertussis toxoid/toxin, Filamentous hemagglutinin, Pertactin and Fimbriae types 2 and 3.
| ELISA units (EU)/mL | Stage II: Group 5 SP0202-IIb | Stage II: Group 6 SP0202-VI | Stage II: Group 7 SP0202-VII | Stage II: Group 8 Prevnar 13 |
|---|---|---|---|---|
| Pertussis toxoid/toxin | 67.9 (60.1 to 76.6) | 77.2 (67.4 to 88.5) | 66.3 (57.4 to 76.6) | 68.3 (59.7 to 78.2) |
| Filamentous hemagglutinin | 109 (94.9 to 124) | 107 (94.4 to 122) | 108 (95.2 to 123) | 104 (93.0 to 116) |
| Pertactin | 38.3 (32.3 to 45.4) | 36.1 (29.4 to 44.3) | 39.8 (32.8 to 48.3) | 45.2 (37.7 to 54.1) |
| Fimbriae types 2 and 3 | 347 (295 to 408) | 341 (286 to 407) | 315 (262 to 380) | 343 (282 to 418) |
Anti-Hepatitis B antibodies were measured by the commercially available VITROS ECi/ECiQ immunodiagnostic system using chemiluminescence detection technology. The VITROS ECi immunodiagnostic system uses an antibody mediated antigen sandwich formation to detect the presence of anti-hepatitis B surface antigen total immunoglobulin in human serum. The threshold presented is \>=10 milli international units (mIU).
| percentage of participants | Stage II: Group 5 SP0202-IIb | Stage II: Group 6 SP0202-VI | Stage II: Group 7 SP0202-VII | Stage II: Group 8 Prevnar 13 |
|---|---|---|---|---|
| For Infants: Percentage of Participants With Antibody Responses to Hepatitis-B Antigens 30 Days Post-Dose 3 | 98.3 (94.2 to 99.8) | 99.1 (94.9 to 100) | 98.1 (93.5 to 99.8) | 99.2 (95.6 to 100) |
Anti-measles antibodies were determined by bulk measles IgG enzyme immunoassay (EIA); anti-mumps antibodies by ELISA, anti-rubella antibodies by bulk rubella IgG EIA and anti-varicella antibodies were determined by glycoprotein ELISA to detect total IgG antibody to respective virus before and after vaccination with a virus-containing vaccine. Percentage of participants with anti-measles antibody concentrations \>=255 mIU/mL, anti-mumps antibody concentrations: \>=10 antibody units/mL, anti-rubella antibody concentrations \>=10 IU/mL and anti-varicella concentrations \>=5 units/mL is reported in this outcome measure.
| percentage of participants | Stage II: Group 5 SP0202-IIb | Stage II: Group 6 SP0202-VI | Stage II: Group 7 SP0202-VII | Stage II: Group 8 Prevnar 13 |
|---|---|---|---|---|
| Anti-Measles | 97.5 (92.7 to 99.5) | 97.1 (91.8 to 99.4) | 96.9 (91.3 to 99.4) | 98.4 (94.3 to 99.8) |
| Anti-Mumps | 99.2 (95.4 to 100) | 97.1 (91.8 to 99.4) | 96.9 (91.3 to 99.4) | 98.4 (94.3 to 99.8) |
| Anti-Rubella | 98.3 (94.0 to 99.8) | 98.1 (93.2 to 99.8) | 99.0 (94.4 to 100) | 98.4 (94.3 to 99.8) |
| Anti-Varicella | 100 (96.9 to 100) | 99.0 (94.8 to 100) | 95.9 (89.9 to 98.9) | 98.4 (94.3 to 99.8) |
Collected over AEs data was collected from first dose vaccine administration (Day 1) until 6 months after the last dose administration, 490 days. All-cause mortality was collected up to end of the study (Stage I: 6 months and Stage II: 19 months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Stage I: Group 1 SP0202-IIb | 0/35 (0%) | 0/35 (0%) | 28/35 (80%) |
| Stage I: Group 2 SP0202-VI | 0/34 (0%) | 1/34 (2.9%) | 28/34 (82.4%) |
| Stage I: Group 3 SP0202-VII | 0/35 (0%) | 0/35 (0%) | 29/35 (82.9%) |
| Stage I: Group 4 Prevnar 13 | 0/34 (0%) | 0/34 (0%) | 25/34 (73.5%) |
| Stage II: Group 5 SP0202-IIb | 0/180 (0%) | 3/180 (1.7%) | 160/180 (88.9%) |
| Stage II: Group 6 SP0202-VI | 1/178 (0.6%) | 9/178 (5.1%) | 164/178 (92.1%) |
| Stage II: Group 7 SP0202-VII | 0/176 (0%) | 8/176 (4.5%) | 159/176 (90.3%) |
| Stage II: Group 8 Prevnar 13 | 0/176 (0%) | 9/176 (5.1%) | 158/176 (89.8%) |
| Event | Stage I: Group 1 SP0202-IIb | Stage I: Group 2 SP0202-VI | Stage I: Group 3 SP0202-VII | Stage I: Group 4 Prevnar 13 | Stage II: Group 5 SP0202-IIb | Stage II: Group 6 SP0202-VI | Stage II: Group 7 SP0202-VII | Stage II: Group 8 Prevnar 13 |
|---|---|---|---|---|---|---|---|---|
| Hand-Foot-And-Mouth DiseaseInfections and infestations | 0/35 | 1/34 | 0/35 | 0/34 | 0/180 | 0/178 | 0/176 | 0/176 |
| PneumoniaInfections and infestations | 0/35 | 0/34 | 0/35 | 0/34 | 1/180 | 0/178 | 1/176 | 2/176 |
| Respiratory Syncytial Virus BronchiolitisInfections and infestations | 0/35 | 0/34 | 0/35 | 0/34 | 0/180 | 2/178 | 1/176 | 0/176 |
| Eyelid PtosisEye disorders | 0/35 | 0/34 | 0/35 | 0/34 | 0/180 | 0/178 | 1/176 | 0/176 |
| HaematocheziaGastrointestinal disorders | 0/35 | 0/34 | 0/35 | 0/34 | 0/180 | 0/178 | 0/176 | 1/176 |
| BronchiolitisInfections and infestations | 0/35 | 0/34 | 0/35 | 0/34 | 0/180 | 1/178 | 0/176 | 1/176 |
| Covid-19Infections and infestations | 0/35 | 0/34 | 0/35 | 0/34 | 0/180 | 0/178 | 0/176 | 1/176 |
| GastroenteritisInfections and infestations | 0/35 | 0/34 | 0/35 | 0/34 | 0/180 | 1/178 | 0/176 | 1/176 |
| Pneumonia InfluenzalInfections and infestations | 0/35 | 0/34 | 0/35 | 0/34 | 0/180 | 0/178 | 1/176 | 0/176 |
| PyelonephritisInfections and infestations | 0/35 | 0/34 | 0/35 | 0/34 | 0/180 | 1/178 | 1/176 | 0/176 |
| Event | Stage I: Group 1 SP0202-IIb | Stage I: Group 2 SP0202-VI | Stage I: Group 3 SP0202-VII | Stage I: Group 4 Prevnar 13 | Stage II: Group 5 SP0202-IIb | Stage II: Group 6 SP0202-VI | Stage II: Group 7 SP0202-VII | Stage II: Group 8 Prevnar 13 |
|---|---|---|---|---|---|---|---|---|
| Injection Site PainGeneral disorders | 16/35 | 12/34 | 19/35 | 13/34 | 120/180 | 127/178 | 125/176 | 124/176 |
| IrritabilityPsychiatric disorders | 21/35 | 16/34 | 22/35 | 20/34 | 110/180 | 116/178 | 114/176 | 117/176 |
| CryingGeneral disorders | 16/35 | 6/34 | 17/35 | 17/34 | 113/180 | 112/178 | 101/176 | 106/176 |
| SomnolenceNervous system disorders | 12/35 | 11/34 | 12/35 | 10/34 | 94/180 | 97/178 | 92/176 | 104/176 |
| Injection Site ErythemaGeneral disorders | 20/35 | 14/34 | 13/35 | 10/34 | 71/180 | 58/178 | 65/176 | 65/176 |
| Injection Site SwellingGeneral disorders | 16/35 | 14/34 | 14/35 | 9/34 | 50/180 | 48/178 | 49/176 | 59/176 |
| Decreased AppetiteMetabolism and nutrition disorders | 9/35 | 7/34 | 13/35 | 11/34 | 70/180 | 70/178 | 68/176 | 67/176 |
| PyrexiaGeneral disorders | 4/35 | 7/34 | 8/35 | 9/34 | 67/180 | 61/178 | 63/176 | 68/176 |
| NasopharyngitisInfections and infestations | 1/35 | 1/34 | 0/35 | 0/34 | 61/180 | 55/178 | 61/176 | 48/176 |
| VomitingGastrointestinal disorders | 3/35 | 0/34 | 2/35 | 3/34 | 43/180 | 36/178 | 43/176 | 45/176 |
| Age, Continuous(years) | Stage I: Group 1 SP0202-IIb | Stage I: Group 2 SP0202-VI | Stage I: Group 3 SP0202-VII | Stage I: Group 4 Prevnar 13 | Stage II: Group 5 SP0202-IIb | Stage II: Group 6 SP0202-VI | Stage II: Group 7 SP0202-VII | Stage II: Group 8 Prevnar 13 | Total |
|---|---|---|---|---|---|---|---|---|---|
| Mean | 1.1 ± 0.11 | 1.1 ± 0.10 | 1.1 ± 0.12 | 1.2 ± 0.11 | 0.2 ± 0.03 | 0.2 ± 0.03 | 0.2 ± 0.03 | 0.2 ± 0.03 | 0.3 ± 0.36 |
| Sex/Gender, Customized(Participants) | Stage I: Group 1 SP0202-IIb | Stage I: Group 2 SP0202-VI | Stage I: Group 3 SP0202-VII | Stage I: Group 4 Prevnar 13 | Stage II: Group 5 SP0202-IIb | Stage II: Group 6 SP0202-VI | Stage II: Group 7 SP0202-VII | Stage II: Group 8 Prevnar 13 | Total |
|---|---|---|---|---|---|---|---|---|---|
| Female | 17 | 12 | 20 | 17 | 93 | 94 | 78 | 90 | 421 |
| Male | 18 | 22 | 15 | 18 | 86 | 84 | 101 | 86 | 430 |
| Missing | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Race/Ethnicity, Customized(Participants) | Stage I: Group 1 SP0202-IIb | Stage I: Group 2 SP0202-VI | Stage I: Group 3 SP0202-VII | Stage I: Group 4 Prevnar 13 | Stage II: Group 5 SP0202-IIb | Stage II: Group 6 SP0202-VI | Stage II: Group 7 SP0202-VII | Stage II: Group 8 Prevnar 13 | Total |
|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 2 | 1 | 0 | 2 | 26 | 26 | 23 | 23 | 103 |
| Asian | 1 | 0 | 2 | 2 | 1 | 0 | 0 | 2 | 8 |
| Black or African American | 5 | 2 | 3 | 6 | 10 | 17 | 10 | 11 | 64 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| White | 24 | 28 | 29 | 25 | 75 | 67 | 79 | 80 | 407 |
| Multiple | 2 | 3 | 0 | 0 | 64 | 67 | 67 | 59 | 262 |
| Not Reported | 0 | 0 | 1 | 0 | 2 | 0 | 0 | 1 | 4 |
| Unknown | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 2 |
| Missing | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Ran from May 2020 to primary completion in Aug 2023, 38 months.
Results were first posted in Nov 2024, 1 year 3 months after primary completion.
Of 17 phase 2 interventional studies under Chickenpox, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 38. This study's 38 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Chickenpox Vaccine · RotaTeq
Sanofi Pasteur, a Sanofi Company →